Literature DB >> 27913533

Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum.

John T Sandlund1,2, Mike G Martin3,4.   

Abstract

The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults. Factors contributing to this discrepancy include psychosocial factors, patient factors, and differences in tumor biology and therapy. These factors will be reviewed, with particular attention to the biological features of diffuse large B-cell lymphoma and anaplastic large cell lymphoma and corresponding therapeutic challenges. Novel targeting agents have been developed, which have been shown to be active in some patients. There is clearly a need for treatment protocols with eligibility criteria that cover the full span of the pediatric and AYA age range and that incorporate detailed molecular characterization of the tumors.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27913533      PMCID: PMC6142492          DOI: 10.1182/asheducation-2016.1.589

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  98 in total

1.  Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

Authors:  A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

2.  Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Margaret Shovlin; Mark Roschewski; Catherine Lai; Seth M Steinberg; Elaine S Jaffe; Wyndham H Wilson
Journal:  Haematologica       Date:  2015-10-30       Impact factor: 9.941

3.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial.

Authors:  Ilske Oschlies; Wolfram Klapper; Martin Zimmermann; Matthias Krams; Hans-Heinrich Wacker; Birgit Burkhardt; Lana Harder; Reiner Siebert; Alfred Reiter; Reza Parwaresch
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

4.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

5.  Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.

Authors:  K W Song; M J Barnett; R D Gascoyne; M Chhanabhai; D L Forrest; D E Hogge; J C Lavoie; S H Nantel; T J Nevill; J D Shepherd; C A Smith; H J Sutherland; C L Toze; N J Voss; J M Connors
Journal:  Ann Oncol       Date:  2006-12-08       Impact factor: 32.976

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 7.  Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.

Authors:  Kelley V Foyil; Nancy L Bartlett
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

8.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

9.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

10.  Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

Authors:  Francesco d'Amore; Thomas Relander; Grete F Lauritzsen; Esa Jantunen; Hans Hagberg; Harald Anderson; Harald Holte; Anders Österborg; Mats Merup; Peter Brown; Outi Kuittinen; Martin Erlanson; Bjørn Østenstad; Unn-Merete Fagerli; Ole V Gadeberg; Christer Sundström; Jan Delabie; Elisabeth Ralfkiaer; Martine Vornanen; Helle E Toldbod
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

View more
  16 in total

1.  Risk of Second Primary Bone and Soft-Tissue Sarcomas Among Young Adulthood Cancer Survivors.

Authors:  Sara J Schonfeld; Diana M Merino; Rochelle E Curtis; Amy Berrington de González; Megan M Herr; Ruth A Kleinerman; Sharon A Savage; Margaret A Tucker; Lindsay M Morton
Journal:  JNCI Cancer Spectr       Date:  2019-06-20

Review 2.  The role of interleukins and the widely studied TNF-α in non-Hodgkin's lymphoma.

Authors:  Kyle P D'mello; Lei Zhao; Erin C Kaser; Ziwen Zhu; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Med Oncol       Date:  2021-04-09       Impact factor: 3.064

Review 3.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 4.  Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective.

Authors:  Kieron Dunleavy; Thomas G Gross
Journal:  Blood       Date:  2018-06-12       Impact factor: 22.113

Review 5.  PET/CT in pediatric oncology.

Authors:  Gabriele Masselli; Cristina De Angelis; Saadi Sollaku; Emanuele Casciani; Gianfranco Gualdi
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-04-15

6.  Retrospective analysis of adolescent and young adult with lymphoma at two cancer facilities in Japan.

Authors:  Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Ryo Saito; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura
Journal:  Leuk Res Rep       Date:  2019-05-25

Review 7.  [Lymphoma in children and adolescents].

Authors:  Ina Sorge; Thomas Walter Georgi; Franz Wolfgang Hirsch
Journal:  Radiologe       Date:  2021-06-23       Impact factor: 0.635

8.  Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases.

Authors:  Changfei Qin; Yuhua Huang; Yanfen Feng; Min Li; Na Guo; Huilan Rao
Journal:  Diagn Pathol       Date:  2018-02-27       Impact factor: 2.644

9.  Age-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma: An In Silico Approach.

Authors:  Eric J Vick; Noah Richardson; Kruti Patel; Glenda M Delgado Ramos; Alaa Altahan; Taylor Alloway; Michael G Martin
Journal:  World J Oncol       Date:  2018-09-06

10.  Unique Raman Spectroscopic Fingerprints of B-Cell Non-Hodgkin Lymphoma: Implications for Diagnosis, Prognosis and New Therapies.

Authors:  B Shiramizu; R Oda; N Kamada; M A Garcia; T Shieh; T A Maeda; S Y Choi; E Lim; A Misra
Journal:  J Biol Med Sci       Date:  2018-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.